Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC
Shots:
- The first patient has been dosed in the P-IIa expansion portion of P- I/IIa study- assessing BT1718 (qw) at RP2D of 20 mg/m2 in patients with MT1-MMP+ sq. NSCLC and a basket of other MT1-MMP+ solid tumors
- The focus of the study is to evaluate the safety and tolerability profiles of BT1718 while the secondary objective is to assess the anti-tumor response. The study is sponsored by Cancer Research UK
- BT1718 is a BTC targeting MT1-MMP and is consist of a mono-hindered disulfide cleavable linker and a cytotoxic DM1 payload
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com